Based on the use of the patient's natural defences, immunotherapy mobilizes the immune system to recognize and destroy cancer cells, and it has revolutionized the treatment of lung cancer.
However, the effectiveness of immunotherapy varies from patient to patient. At present, we have no weak markers to predict with certainty the efficacy of immunotherapy treatment in a given individual.
Current scientific data identifies a number of molecules produced by the cancer cells and their environment which can be detected by various means (blood tests, breath analysis, etc.).
The aim of this study is to understand whether the amount of nitric oxide (NO) present in the breath is a more accurate predictor of response to immunotherapy.
Participation in this study involves breath testing (to measure FeNO (Fractional exhaled Nitric Oxide)) before receiving the first infusion of immunotherapy, and at the follow-up visit after the 4th course of immunotherapy.
Patients with metastatic NSCLC
Patient not previously treated
PD-L1 tumor expression > 50%, to be treated with immunotherapy alone after validation by a multidisciplinary consultation meeting.
Patients over 18 years of age
Patients previously treated for NSCLC
Patient with oncogene addiction or a first-line targetable rearrangement
Patient not suitable for immunotherapy alone
Patient having received corticosteroid treatment in the 15 days prior to FeNO.
Patients with metastatic non-small-cell lung cancer requiring immunotherapy alone
Cohort
Prospective
Measurement of FeNO
Other interventionBefore the first immunotherapy infusion and at the follow-up visit after the 4th course of immunotherapy
Response to immunotherapy by CT scan
Evaluation according to RECIST criteria by comparing FeNO levels between patients responding and not responding to immunotherapy.
Click on the lead sponsor to view all of their trials.
